Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 2/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 5/20 | 0.33 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.32 |
| ▸ | RORC | P51449 | 1/20 | 0.32 |
| ▸ | GHSR | Q92847 | 1/20 | 0.32 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.32 |
| ▸ | SCN10A | Q9Y5Y9 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | AGER | Q15109 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.31 |
| ▸ | RAF1 | P04049 | 2/20 | 0.30 |
| ▸ | BRAF | P15056 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1660744 | 0.92 | PDE2A (0.38) | PDE2ASCN9AP2RY14MAP2K4SCN10A | |
| SCHEMBL14718861 | 0.91 | PDE2A (0.37) | PDE2ASCN9ASCN10AGRIN1GRIN2B | |
| SCHEMBL14727913 | 0.91 | TRPM2 (0.37) | PDE2ASCN9AP2RY14MAP2K4GRIN1 | |
| SCHEMBL14727911 | 0.86 | GRIN2B (0.34) | PDE2ASCN9ASCN10AGRIN1GRIN2B | |
| SCHEMBL14718043 | 0.85 | GRIN2B (0.32) | PDE2ASCN9ASCN10AGRIN1GRIN2B | |
| SCHEMBL6904513 | 0.85 | SCN9A (0.36) | SCN9AGRIN1GRIN2B | |
| SCHEMBL1660015 | 0.85 | PDE2A (0.36) | PDE2ASCN9AP2RY14MAP2K4SCN10A | |
| SCHEMBL6904357 | 0.85 | SRPK1 (0.36) | PDE2ASCN9AGRIN1GRIN2BPIK3CD | |
| SCHEMBL6903551 | 0.84 | PDE2A (0.36) | PDE2ASCN9AP2RY14MAP2K4SCN10A | |
| SCHEMBL14717866 | 0.79 | PDE2A (0.39) | PDE2ASCN9AP2RY14SCN10AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| WO-2011046774-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | BACE1, BACE2, GSAP | PDE2A 4176/4885SCN9A 1887/4885P2RY14 2139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.